SCHEMBL7144947

SCHEMBL7144947

Clc1ccc(-c2c[nH]c(-c3ccc(Cl)cc3Cl)n2)c(Cl)c1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 2/20 0.47
HSP90AB1 P08238 2/20 0.47
LMNA P02545 1/20 0.45
GUSB P08236 1/20 0.43
ALPL P05186 4/20 0.43
CXCR2 P25025 3/20 0.42
KMT2A Q03164 2/20 0.41
PIK3CA P42336 1/20 0.41
PIK3CB P42338 1/20 0.41
PIK3CG P48736 1/20 0.41
MEN1 O00255 1/20 0.41
MAPT P10636 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
AHR P35869 1/20 0.40
NPBWR1 P48145 1/20 0.40
HSD11B1 P28845 1/20 0.40
MAPK1 P28482 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28573837 0.88 SMN1; SMN2 (0.44) HSP90AA1HSP90AB1LMNAALPLCXCR2
SCHEMBL31305450 0.85 DPP4 (0.49) LMNAGUSBCXCR2KMT2AMEN1
SCHEMBL3137641 0.85 DPP4 (0.49) LMNAGUSBCXCR2KMT2AMEN1
SCHEMBL3135986 0.85 ALDH1A1 (0.47) HSP90AA1HSP90AB1LMNAGUSBALPL
SCHEMBL31305456 0.85 ALDH1A1 (0.47) HSP90AA1HSP90AB1LMNAGUSBALPL
SCHEMBL7143281 0.85 DPP4 (0.45) HSP90AA1HSP90AB1GUSBCXCR2HSD11B1
SCHEMBL28402512 0.84 HSP90AA1 (0.41) HSP90AA1HSP90AB1LMNAGUSBALPL
SCHEMBL28406418 0.84 GCGR (0.43) HSP90AA1HSP90AB1LMNAALPLKMT2A
SCHEMBL28406411 0.83 HSP90AA1 (0.40) HSP90AA1HSP90AB1LMNAGUSBALPL
SCHEMBL4269229 0.83 MAPT (0.41) HSP90AA1HSP90AB1LMNAALPLKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6515133-B1 Certain diaryl imidazoles act as partial agonists or antagonists for NPY receptors, in particular NPY 5 receptors. They are of use, for example in treating loss of appetite. Such compounds bear aryl groups in the 2 position. NEUROGEN CORPORATION 2003-02-04 US disclosed
US-6121260-A Method of treating conditions susceptible to modulation of NPY receptors with diarylimidazole derivatives NEUROGEN CORPORATION (US) 2000-09-19 US disclosed
EP-0996443-A1 CERTAIN DIARYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF NPY SPECIFIC LIGANDS NEUROGEN CORPORATION (US) 2000-05-03 EP disclosed
WO-1999001128-A1 CERTAIN DIARYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF NPY SPECIFIC LIGANDS NEUROGEN CORPORATION (US) 1999-01-14 WO disclosed